电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Seryl-tRNA Synthetase (SARS) (AA 2-233) 抗体

This anti-Seryl-tRNA Synthetase antibody is a 兔 多克隆 antibody detecting Seryl-tRNA Synthetase in WB, ELISA 和 IHC. Suitable for 人.
产品编号 ABIN7626679
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for Seryl-tRNA Synthetase (SARS) (AA 2-233) 抗体 (ABIN7626679)

抗原

See all Seryl-tRNA Synthetase (SARS) 抗体
Seryl-tRNA Synthetase (SARS)

适用

  • 29
  • 15
  • 15
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1

宿主

  • 28
  • 2

克隆类型

  • 29
  • 1
多克隆

标记

  • 19
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
非结合性

应用范围

  • 20
  • 10
  • 9
  • 5
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
  • 抗原表位

    • 5
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    AA 2-233

    原理

    Sars Polyclonal Antibody

    产品特性

    The Sars Polyclonal Antibody (Species: Human) has been validated for the following applications: ELISA, WB, IHC.

    纯化方法

    Protein G Purified

    纯度

    >95%

    免疫原

    Recombinant Human Serine--Trna Ligase, Cytoplasmic Protein

    亚型

    IgG
  • 应用备注

    Optimal working dilution should be determined by the investigator.

    限制

    仅限研究用
  • 状态

    Liquid

    浓度

    Lot specific

    缓冲液

    Preservative: 0.03 % Proclin 300, Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

    储存液

    ProClin

    注意事项

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    储存条件

    4 °C,-20 °C

    储存方法

    2°C to 8°C for frequent use, -20°C for 12 months. Avoid repeated freeze/thaw cycles.

    有效期

    12 months
  • 抗原

    Seryl-tRNA Synthetase (SARS)

    别名

    SARS

    UniProt

    P49591
You are here: